Generate Biomedicines, Inc.
Generate Biomedicines, Inc. scores highest on Anchor (63) and lowest on Price (19). Its PosiPenta is 40.10 out of 100, around the middle of similar companies.
On the Penta Grid this week, Generate Biomedicines, Inc. is Grid #537 of 837 in the Healthcare sector in United States, and Grid #2,874 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Generate Biomedicines, Inc. | 40.10 | 19 | 27 | 44 | 47 | 63 |
| Novavax, Inc. | 56.50 | 0 | 56 | 85 | 97 | 44 |
| Nuvation Bio Inc. | 42.05 | 11 | 70 | 43 | 31 | 55 |
| Sonida Senior Living, Inc. | 49.16 | 29 | 40 | 77 | 37 | 62 |
| Hemab Therapeutics Holdings, Inc. | 49.46 | 21 | 33 | 51 | 81 | 60 |
| Stoke Therapeutics, Inc. | 39.82 | 15 | 21 | 54 | 59 | 50 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.95 |
| P/B ratio | 3.40 |
EEarnings
| Trailing EPS | ₹-231.10 |
| Forward EPS | ₹-215.95 |
NNitro
| Price | 1145.10 |
| 52-week high | 2147.19 |
| 52-week low | 1041.86 |
| Fall from 52-week high | 46.7% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 0.14 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹14,697 Cr |
| Insider holding | 14.05% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Generate Biomedicines, Inc.'s PosiPenta score?
Generate Biomedicines, Inc.'s PosiPenta is 40.10 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Generate Biomedicines, Inc. stand on the Penta Grid?
On the Penta Grid this week, Generate Biomedicines, Inc. is Grid #537 of 837 in the Healthcare sector in United States, and Grid #2,874 of 4,000 in United States.
Which PosiPenta pillar is strongest for Generate Biomedicines, Inc.?
Anchor (stability and dividends), with a score of 63 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Generate Biomedicines, Inc.?
Price (valuation), with a score of 19 out of 100: much weaker than most similar companies.
Has Generate Biomedicines, Inc.'s PosiPenta changed since last week?
Yes, it rose 1.29 points, from 38.81 to 40.10.
PositoAI is for research and education only and is not investment advice.